[The effect of one year therapy with recombinant human growth hormone (rhGH) on growth velocity, calcium-phosphorus metabolism, bone mineral density and changes in body composition in children with growth hormone deficiency (GHD)].

What Was Tested

This clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Comparison between the rate of growth and estimation of calcium-phosphorus metabolism, bone mineral density and change of body composition in children with growth hormone deficiency during the first year of growth hormone treatment.

Why It Was Studied

For adults the metabolic effect is the most important.

This treatment has an influence on the forming of correct composition of body mass, on metabolism of osseous tissue and bone mineral density.

Who Took Part

The abstract describes 120 children taking part.

The age groups tagged for this paper are children, teenagers, young adults and adults, both men and women.

The treatment included 120 children and adolescents (85 boys and 35 girls) in age from 6 to 21.5 years old (the average age: 14.2+/-3.0) who were treated in Dept. of Endocrinology and Diabetology for Children and Adolescents during the years 2002-2006 as a result of growth hormone deficiency.

Children suffering from panhypopituitarism and other diseases were excluded from the research.

How the Study Was Run

The following parameters were included in the analysis: age and sex, age at the start of treatment, the degree of growth hormone deficiency, concentration of calcium, magnesium and phosphates in blood serum, mineral density of bones (BMD), the concentration of osseous minerals, concentration of adipose tissue and lean body mass.

No interruption of the treatment was noticed.

What Was Measured

PubMed files the paper under topics including Alkaline Phosphatase, Body Composition, Bone Density, Calcium, Growth, Growth Disorders and Human Growth Hormone.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 120 children.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2010 (Pediatric endocrinology, diabetes, and metabolism), a journal based in Poland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.